Key Takeaways
- PT-141 (bremelanotide) acts on melanocortin receptors involved in sexual desire, while kisspeptin regulates reproductive hormones.
- In two 24-week phase 3 trials, injectable bremelanotide (Vyleesi) improved sexual desire and related distress in premenopausal women with HSDD.
- Injectable bremelanotide is approved for acquired, generalized HSDD in premenopausal women; other uses are off-label, and compounded PT-141 formats are not FDA-approved.
- Small human studies have examined kisspeptin's effects on sexual brain processing and reproductive hormone responses, but kisspeptin is not FDA-approved for sexual dysfunction.
- Rebody offers clinician-led access to compounded PT-141 troches, nasal spray, strips, and PT-141 + oxytocin tablets, subject to provider approval.
PT-141 acts on melanocortin receptors in the brain to influence desire. Kisspeptin works upstream on reproductive hormones and remains investigational.
PT-141 is available by prescription as the approved injection or, off-label, as a compounded needle-free PT-141 format such as a troche or nasal spray. Kisspeptin has been studied in clinical trials for low desire and fertility.
The difference between PT-141 and kisspeptin
| Factor | PT-141 (Bremelanotide) | Kisspeptin |
|---|---|---|
| Where it acts | Melanocortin receptors (MC3R and MC4R) in the brain | GnRH release, plus limbic brain regions |
| Hormone research | Trials measured desire, distress, and erections; hormones were not study outcomes | Raised LH, FSH, and testosterone in an infusion study of 6 healthy men |
| Main human evidence | Two phase 3 trials (1,267 women) plus early trials in men | Single-session trials of 29 to 32 people each |
| FDA status | Approved as Vyleesi for one indication; compounded forms are not approved and are prescribed off-label | Not approved; kisspeptin-10 is on FDA's category 2 compounding list |
| Formats | Autoinjector (Vyleesi); compounded troches, nasal spray, strips, and combination products | Research formulations |
| Common side effects | Nausea, flushing, headache, temporary blood pressure rise | None reported in the 32-person trial |
| How to get it | Prescription from a licensed clinician | Clinical trials |
How does PT-141 work?
PT-141, also known as bremelanotide, is a synthetic peptide derived from the hormone alpha-melanocyte-stimulating hormone (alpha-MSH). It activates several melanocortin receptors.
The FDA label names MC1R and MC4R as the most relevant receptors. MC4R neurons are present in many areas of the central nervous system, while MC1R sits on skin pigment cells, where binding increases pigmentation.
PT-141 works differently from phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil and tadalafil. PDE5 inhibitors support erectile function by relaxing blood vessels, while PT-141 acts on central signaling pathways.
The exact mechanism responsible for bremelanotide's clinical effects in HSDD has not been fully established. However, the RECONNECT phase 3 trials published in Obstetrics & Gynecology demonstrated improvements in sexual desire and related distress with injectable bremelanotide.
How does kisspeptin work?
Kisspeptin is a neuropeptide encoded by the KISS1 gene. It helps regulate the hypothalamic-pituitary-gonadal (HPG) axis, which controls reproductive hormone signaling. Its longest form, kisspeptin-54, was originally called metastin.
Kisspeptin signals directly to the neurons that release gonadotropin-releasing hormone (GnRH), which regulates the release of two hormones from the pituitary gland:
- Luteinizing hormone (LH): Supports testosterone production in men and ovulation-related processes in women.
- Follicle-stimulating hormone (FSH): Contributes to sperm production and ovarian follicle development.
Kisspeptin also influences brain regions associated with sexual attraction and emotional responses to sexual stimuli. In a study involving 29 healthy young men, intravenous kisspeptin increased activity in limbic brain regions when participants viewed sexual and couple-bonding images.
Comparing PT-141 and kisspeptin sexual benefits
PT-141 has the stronger evidence base for treating low sexual desire in premenopausal women with HSDD. Kisspeptin has shown effects on sexual brain processing in smaller studies involving men and women.
| What was measured | PT-141 | Kisspeptin |
|---|---|---|
| Sexual desire | Improved desire and related distress in two 24-week phase 3 trials that randomized 1,267 premenopausal women with HSDD; according to FDA's approval announcement, the number of satisfying sexual events did not change significantly | A single IV infusion altered brain responses to sexual and attraction cues in 32 premenopausal women with HSDD |
| Erectile function | 2004 nasal-spray study in 30 healthy men and 24 men with sildenafil-responsive ED that measured erectile response | A single infusion increased penile rigidity during sexual videos by up to 56% versus placebo in 32 men with HSDD |
How do PT-141 and kisspeptin affect hormones?
Kisspeptin stimulates reproductive hormone signaling through the GnRH pathway, while PT-141 primarily acts on melanocortin receptors involved in sexual response.
Across human studies using different forms and methods, kisspeptin consistently stimulated LH secretion. Researchers have also investigated kisspeptin for reproductive applications. In a trial of 53 women with subfertility undergoing in vitro fertilization (IVF), a single kisspeptin-54 injection triggered egg maturation, and 12 women (23%) had a clinical pregnancy.
If your goal is supporting your own testosterone production, ask a clinician about oral enclomiphene, which raises LH and FSH by blocking estrogen feedback in the brain. Compounded enclomiphene is not FDA-approved and is prescribed off-label.
PT-141 formats and how kisspeptin is given
| Format | Status | Strength and package | What to know |
|---|---|---|---|
| Vyleesi autoinjector | FDA approved | 1.75 mg prefilled injection | Approved for acquired, generalized HSDD in premenopausal women; included for reference and not offered by Rebody |
| PT-141 troches | Compounded, off-label | 2 mg; 8 per package | Sublingual troche; no needle |
| PT-141 strips | Compounded, off-label | 2 mg; 24 per package | Thin dissolving film |
| PT-141 nasal spray | Compounded, off-label | 5 mg/mL in a 3 mL bottle | The method used in early human bremelanotide studies |
| PT-141 + oxytocin dissolving tablets | Compounded, off-label | 1 mg PT-141 + 20 IU oxytocin, or 2 mg + 40 IU; 8 per package | Dissolving tablet; pairs PT-141 with oxytocin |
The four compounded formats are not FDA-approved. A licensed U.S. 503A compounding pharmacy prepares each one for your prescription, and your clinician sets your dose and directions.
In the sexual-health trials, kisspeptin was given by IV infusion; fertility research has used an injection.
PT-141 and kisspeptin side effects and risks
The approved PT-141 injection has safety data from large phase 3 trials, and most reported reactions were mild or moderate and short-lived. Kisspeptin's sexual-health safety data come from small, short studies.
For the FDA-approved bremelanotide injection, the label reports:
- Common reactions: nausea (40%), flushing (20%), reactions where the injection was given (13%), and headache (11%). Nausea was most common early in treatment and usually lasted about two hours.
- Blood pressure and heart rate: a temporary rise in blood pressure (up to 6 mmHg systolic) and fall in heart rate, usually back to baseline within 12 hours. The approved injection is contraindicated in uncontrolled hypertension or known cardiovascular disease.
- Skin darkening: focal hyperpigmentation of the face, gums, or breasts in 1% of trial patients.
- Medicines: bremelanotide can slow gastric emptying and reduce absorption of some oral drugs, and it separately lowers levels of oral naltrexone.
These rates come from the injection. Tell your clinician if you are pregnant or could be; formats with oxytocin aren't for anyone who is or could be pregnant.
Kisspeptin was well tolerated, with no adverse effects reported, in the randomized trial of 32 premenopausal women with HSDD. That trial tested short-term intravenous infusions, so it doesn't establish long-term safety or the safety of other kisspeptin formulations.
Which is better for libido: PT-141 or kisspeptin?
PT-141 is the better-supported choice for libido, and a clinician can prescribe it. Vyleesi fits premenopausal women within its label. Compounded PT-141, prescribed off-label, lets a clinician choose a format and strength for your goals.
If your goal is hormonal or fertility support, start with hormone labs and a clinician's review. Legitimate access to kisspeptin is through clinical research.
Choosing between PT-141 and kisspeptin with a clinician
PT-141 has the stronger clinical backing for desire and arousal, and it's the one a clinician can prescribe today. Kisspeptin works on reproductive hormones and has been studied in trials.
With Rebody, a licensed clinician reviews your goals and health history, a licensed U.S. 503A pharmacy prepares the PT-141 format you're prescribed, and your care team follows up on side effects, strength, and format.
Start an online visit to see whether PT-141 fits your goals.
Frequently Asked Questions (FAQs)
Is kisspeptin FDA-approved?
No. FDA placed kisspeptin-10 on its Category 2 compounding list in September 2023, citing immunogenicity risk, peptide-related impurities, and difficulty characterizing the active ingredient.
Can you take PT-141 and ED medications together?
Only with a clinician's review. These medications work through different mechanisms, but combining them requires a review of blood pressure, heart health, current medications, and potential adverse effects.
Can you take PT-141 and kisspeptin together?
No human studies have tested the combination, and kisspeptin isn't an approved or prescribable treatment.
What is PT-141 peptide injection used for?
The FDA-approved bremelanotide injection treats acquired, generalized hypoactive sexual desire disorder in premenopausal women. Compounded PT-141, which is not FDA-approved, is prescribed off-label for low desire in other adults, as troches, nasal spray, strips, and PT-141 + oxytocin tablets.
How do you stimulate kisspeptin?
Kisspeptin is produced naturally as part of the reproductive hormone system. Researchers have administered kisspeptin to study its effects on GnRH and LH signaling, but there is no FDA-approved kisspeptin treatment for increasing sexual desire.
Is PT-141 or kisspeptin better for low libido?
PT-141 has stronger clinical evidence for acquired, generalized HSDD in premenopausal women. Kisspeptin has shown effects on sexual brain processing in early studies but remains investigational.
This article is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional about your health or before changing treatment. Do not delay medical care because of something you read here.